Thus, the evoke/evoke+ trials could provide a much needed catalyst for Novo Nordisk, especially following the questions raised by REDEFINE 1 around CagriSema, despite the latter delivering perfectly reasonable weight loss
The molecular physiology of uric acid homeostasis

GLP-1 Agonists Market Segmentation Analysis Key Features of the Report The GLP-1 agonist market report provides granular level information about the market size, regional market share, historic market (2021-2025), and forecast (2026-2032) The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market The report tracks recent innovations, key developments, and start-up details that are actively working in the market The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis Download Free Sample Report Frequently Asked Questions GLP-1 agonists market size was valued at US$ 37,113.2 billion in 2025 and is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026-2032 The focus on cardiovascular outcomes trials (CVOTs) and the accompanying excellent results have elevated the profile of GLP-1 agonists, making them more appealing to healthcare practitioners looking for complete diabetes management

Without insurance coverage, FDA-approved brand-name GLP-1 medications can run significantly higher at retail - often $900 to $1,300+ per month without insurance - placing evidence-based pharmacotherapy out of reach for the majority of patients who could clinically benefit
All applications are limited to controlled scientific research